Pfizer Inc (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Ticker
- PFE
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $164.50B
- 52-week range
- $23.62 - $31.44
Valuation
- Share price
- $28.88 (close of Nov 16, 2026)
- P/E (TTM)
- 40.08x
- Price to book
- 1.84x
- Price to free cash flow
- 13.96x
- Enterprise value
- $216.23B
- Book value per share
- $15.67
Price performance
| Period | Change |
|---|---|
| 1 day | -0.03% |
| 5 days | -1.20% |
| 1 month | -2.37% |
| 3 months | +7.80% |
| 6 months | +14.02% |
| Year to date | +15.98% |
| 1 year | +15.24% |
| 3 years | -2.98% |
| 5 years | -41.77% |
| 10 years | -4.75% |
| All time | +3,442.05% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 2.36%
- Shares short
- 134.42M
- Days to cover
- 4.58
- Change since prior report
- -2.46%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed PFE trades
Gilbert Ray Cisneros · Robert Bresnahan · Bruce Westerman · Carol Miller · Jefferson Shreve · Julie Johnson · Lisa McClain · Tommy Tuberville · Alan Armstrong · French Hill · John Boozman · Josh Gottheimer
Super investors holding PFE
Ken Griffin (Citadel) · Richard Pzena (Pzena Investment Management) · Harry Burn (Sound Shore Management) · Sarah Ketterer (Causeway Capital Management LLC) · Prem Watsa (Fairfax Financial Holdings) · Kahn Brothers (Kahn Brothers Group) · Bruce Berkowitz (Fairholme Capital) · Ray Dalio (Bridgewater Associates) · Hillman Capital (Hillman Capital Management, Inc) · Dodge & Cox (Dodge & Cox Funds) · Mairs & Power (Mairs & Power Inc)
Profitability and growth
- Return on equity
- 8.96%
- Return on invested capital
- 6.76%*
- Return on assets
- 3.73%
- Return on capital employed
- 5.95%*
- Gross margin
- 74.33%
- Net margin
- 12.42%
- EBITDA margin
- 26.79%
- Revenue growth
- -1.65%
- Net income growth
- -3.24%
- Free cash flow growth
- -7.73%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.16%
- Current ratio
- 1.42x
- Net debt to EBITDA
- 3.84x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $62.58B
- Cost of revenue
- $16.07B
- Gross profit
- $46.51B
- EBITDA
- $16.77B
- Net income
- $7.77B
- Earnings per share
- $1.37
- Research and development
- $10.44B
- Interest expense
- $2.67B
- Shares outstanding
- 5.68B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $62.58B | $46.51B | $7.77B | $1.37 |
| 2024-12-31 | $63.63B | $45.78B | $8.03B | $1.42 |
| 2023-12-31 | $50.91B | $25.96B | $2.12B | $0.38 |
| 2022-12-31 | $91.79B | $57.45B | $31.37B | $5.59 |
| 2021-12-31 | $73.64B | $42.81B | $21.98B | $3.92 |
| 2020-12-31 | $41.65B | $33.17B | $9.16B | $1.65 |
| 2019-12-31 | $40.91B | $32.85B | $16.03B | $2.88 |
| 2018-12-31 | $40.83B | $31.84B | $11.15B | $1.90 |
| 2017-12-31 | $52.55B | $41.32B | $21.31B | $3.57 |
| 2016-12-31 | $52.82B | $40.50B | $7.21B | $1.18 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 74.33% | 12.42% | 8.96% | 6.76%* |
| 2024-12-31 | 71.94% | 12.62% | 9.07% | 7.30%* |
| 2023-12-31 | 50.99% | 4.16% | 2.37% | 2.04%* |
| 2022-12-31 | 62.59% | 34.18% | 32.71% | 24.96%* |
| 2021-12-31 | 58.14% | 29.85% | 28.37% | 19.98%* |
| 2020-12-31 | 79.63% | 21.99% | 14.43% | 7.75%* |
| 2019-12-31 | 80.31% | 39.18% | 25.26% | 10.53%* |
| 2018-12-31 | 77.99% | 27.32% | 17.49% | 4.65%* |
| 2017-12-31 | 78.63% | 40.55% | 29.74% | 11.79%* |
| 2016-12-31 | 76.67% | 13.66% | 12.06% | 8.26%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $10.32B | $61.64B |
| 2024-12-31 | $11.92B | $57.41B |
| 2023-12-31 | $7.25B | $61.54B |
| 2022-12-31 | $19.16B | $32.88B |
| 2021-12-31 | $23.96B | $36.20B |
| 2020-12-31 | $11.49B | $37.13B |
| 2019-12-31 | $9.65B | $35.95B |
| 2018-12-31 | $18.83B | $32.91B |
| 2017-12-31 | $19.99B | $33.54B |
| 2016-12-31 | $17.85B | $31.40B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $9.07B | $799.00M |
| 2024-12-31 | $9.84B | $877.00M |
| 2023-12-31 | $4.79B | $525.00M |
| 2022-12-31 | $26.03B | $872.00M |
| 2021-12-31 | $29.87B | $1.18B |
| 2020-12-31 | $12.18B | $755.00M |
| 2019-12-31 | $10.54B | $687.00M |
| 2018-12-31 | $13.84B | $923.00M |
| 2017-12-31 | $14.85B | $840.00M |
| 2016-12-31 | $14.37B | $691.00M |
Dividend history
- Most recent payment
- Nov 6, 2026
- Paid in the last twelve months
- $1.72
| Payment date | Dividend per share |
|---|---|
| 2026-11-06 | $0.43 |
| 2026-07-24 | $0.43 |
| 2026-05-08 | $0.43 |
| 2026-01-23 | $0.43 |
| 2025-11-07 | $0.43 |
| 2025-07-25 | $0.43 |
| 2025-05-09 | $0.43 |
| 2025-01-24 | $0.43 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-03 | Sep 2026 | $0.72 |
| 2026-08-04 | Jun 2026 | $0.68 |
| 2026-05-05 | Mar 2026 | $0.71 |
| 2026-02-03 | Dec 2025 | $0.57 |
| 2025-11-04 | Sep 2025 | $0.66 |
| 2025-08-05 | Jun 2025 | $0.58 |
| 2025-04-29 | Mar 2025 | $0.64 |
| 2025-02-04 | Dec 2024 | $0.48 |
Filings and sources
- Company website
- pfizer.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Bristol Myers Squibb Co (BMY) · Gilead Sciences, Inc. (GILD) · Biogen Inc. (BIIB) · Amgen Inc (AMGN) · Organon & Co. (OGN) · AstraZeneca plc (AZN) · GSK plc (GSK) · Novartis AG (NVS)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades